We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Web Microsite Introduces Single Cell Gene Expression Profiling

By LabMedica International staff writers
Posted on 22 Dec 2009
A Web microsite introduces the rapidly expanding field of single cell gene expression profiling.

Historically, gene expression profiling of single cells, such as stem cells, circulating tumor and formalin-fixed, paraffin-embedded (FFPE) tissues has been difficult and expensive to perform. More...
Now, however, results from single-cell samples can be obtained easily and inexpensively using the Fluidigm Corp's (South San Francisco, CA, USA) BioMark system and the company's Dynamic Array integrated fluidic circuits (IFCs). Dynamic Array IFCs are ideally suited for high-throughput cell-line studies to determine individual cell behavior in a homozygous population.

Visitors to Fluidigm Web site (see below) can gain an understanding of the technology, find out how international scientists using Fluidigm Dynamic Array chips are accelerating their research, and evaluate whether IFC technology is suitable for their project.

A five-minute audiovisual presentation provides an informative introduction to how IFC technology is now providing a practical means of studying single cells A wide selection of downloadable customer conference posters, peer-reviewed publications, success stories and application notes describe the technology in action and the benefits it is delivering to leading laboratories around the world.

Fluidigm develops, manufactures, and markets proprietary IFC systems that improve productivity in life-science research. Fluidigm's IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology” are made possible by miniaturizing and integrating liquid-handling components on a single microfabricated microfluidic device. Fluidigm's IFC systems, consisting of instrumentation, software, and single-use IFCs, increase throughput, decrease costs, and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the U.S. Food and Drug Administration (FDA) for use as a diagnostic and are only available for research use.

Related Links:
Fluidigm single cell analysis presentation
Fluidigm



New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Pipette Calibration System
Artel PCS®
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.